First Clinical Data from the Investigator-initiated study with CLS Focal Laser Ablation system at the University Hospital Magdeburg will be presented at the Nordkongress in Lübeck 13-15 June 2024

Lund, Sweden - CLS today announces that first clinical data from the PRO-FLA study (Fokale Laserablation (FLA) zur fokalen Behandlung des lokal begrenzten Prostata-karzinoms) using the CLS TRANBERG® Thermal Therapy system for focal laser ablation will be presented at the Nordkongress in Lübeck 13-15 June 2024. An abstract with the title “Ultrasound-guided Focal Laser Ablation in Localized Prostate Cancer within the Pro-FLA Study – Oncological outcome after 6 months” has been accepted for an oral presentation to be held 13 June.

The presentation is part of the scientific program of the conference and the abstract is available here https://www.nordkongress-urologie.de/2024/programm/ (in German).

 

In the abstract the authors (M. Gür, C. Samtleben, A. Fehr, M. Schostak and S. Blaschke) conclude that the PRO-FLA study demonstrates technical feasibility and safety of transperineal focal laser ablation. Early results show promising PSA response as well as good local response, i.e. tumor control.

 

Based on these positive interim results the clinical team at Otto-von-Guericke University, Magdeburg, Clinic for urology, uro-oncology, robot-assisted and focal therapy has decided to extend the study by 15 additional patients. Local ethical committee approval is received for the study extension.

 

About Otto-von-Guericke-University Magdeburg

Otto-von-Guericke-University Magdeburg was founded after the unification of Germany and is one of the important universities in the country. Its medical department is ranked among the top 15 in Germany. The Urology department is a strong and important player in focal therapy of prostate cancer.

 

About prostate cancer

About 1,400,000 new cases per year of prostate cancer are reported worldwide with approximately 350.000 of them within EU. Although the landscape of prostate cancer treatment shows several treatment options, there is still an important unmet need for patients with localized prostate cancer who progressed to intermediate risk stage. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.

 

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-mail: [email protected]

 

About CLS and TRANBERG

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se.